Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 4, 2004 - Issue 3
Submit an article Journal homepage
75
Views
52
CrossRef citations to date
0
Altmetric
Review

Therapeutic potential of retroviral RNAi vectors

Eric Devroe Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. [email protected]
&
Pamela A Silver Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. [email protected]
Pages 319-327 | Published online: 03 Mar 2005

Bibliography

  • CAPLEN NJ, PARRISH S, IMANI F, FIRE A, MORGAN RA: Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA (2001) 98:9742–9747.
  • ELBASHIR SM, HARBORTH J, LENDECKEL W et al.: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411:494–498.
  • PADDISON PJ, HANNON GJ: RNA interference: the new somatic cell genetics? Cancer Cell (2002) 2:17–23.
  • PADDISON PJ, HANNON GJ: siRNAs and shRNAs: skeleton keys to the human genome. Curr. Opin. Mol. Ther. (2003) 5:217–224.
  • SCHERR M, MORGAN MA, EDER M:Gene silencing mediated by small interfering RNAs in mammalian cells. Curr. Med. Chem. (2003) 10:245–256.
  • SHI Y: Mammalian RNAi for the masses. Trends Genet. (2003) 19:9–12.
  • SHUEY DJ, MCCALLUS DE, GIORDANO T: RNAi: gene-silencing in therapeutic intervention. Drug Discov. Today (2002) 7:1040–1046.
  • WALL NR, SHI Y: Small RNA: can RNA interference be exploited for therapy? Lancet (2003) 362:1401–1403.
  • CAPLEN NJ: RNAi as a gene therapy approach. Expert Opin. Biol. Ther. (2003) 3:575–586.
  • AGAMI R: RNAi and related mechanisms and their potential use for therapy. Can: Opin. Chem. Biol. (2002) 6:829–834.
  • LIEBERMAN J, SONG E, LEE SK, SHANKAR P: Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol. Med. (2003) 9:397–403.
  • PADDISON PJ, CAUDY AA, BERNSTEIN E, HANNON GJ, CONKLIN DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. (2002) 16:948–958.
  • SUI G, SOOHOO C, AFFAR EL B et al.:A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA (2002) 99:5515–5520.
  • YU JY, DERUITER SL, TURNER DL: RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Nati Acad. Set. USA (2002) 99:6047–6052.
  • MIYAGISHI M, TAIRA K: U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. Nat. Biotechnol. (2002) 20:497–500.
  • PAUL CP, GOOD PD, WINER I, ENGELKE DR: Effective expression of small interfering RNA in human cells. Nat. Biotechnol. (2002) 20:505–508.
  • KWAK YD, KOIKE H, SUGAYA K: RNA Interference with small hairpin RNAs transcribed from a human U6 promoter- driven DNA vector. Pharmacol. Sri. (2003) 93:214–217.
  • BRUMMELKAMP TR, BERNARDS R, AGAMI R: A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 296:550–553.
  • BODEN D, PUSCH O, LEE F et al.: Promoter choice affects the potency of HIV-1 specific RNA interference. Nucleic Acids Res. (2003) 31:5033–5038.
  • KAWASAKI H, TAIRA K: Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res. (2003) 31:700–707.
  • XIA H, MAO Q, PAULSON HL, DAVIDSON BL: siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. (2002) 20:1006–1010.
  • DEVROE E, SILVER PA: Retrovirus-delivered siRNA. BMC Biotechnol. (2002) 2:15.
  • BRUMMELKAMP TR, BERNARDS R, AGAMI R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 2:243–247.
  • ••Demonstrates that retroviral RNAi vectorscan selectively silence the K-RASV12 oncogene and completely block tumour formation in nude mice.
  • BARTON GM, MEDZHITOV R: Retroviral delivery of small interfering RNA into primary cells. Proc. Nati Acad. Sci. USA (2002) 99:14943–14945.
  • ABBAS-TERKI T, BLANCO-BOSE W, DEGLON N, PRALONG W, AEBISCHER P: Lentiviral-mediated RNA interference. Hum. Gene Ther. (2002) 13:2197–2201.
  • RUBINSON DA, DILLON CP, KWIATKOWSKI AV et al.: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. (2003) 33:401–406.
  • •One of several reports describing the use of lentiviral RNAi vectors to generate knockdown mice.
  • STEWART SA, DYKXHOORN DM, PALLISER D et al.: Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 9:493–501.
  • TISCORNIA G, SINGER O, IKAWA M, VERIVIA IM: A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Nati Acad. Sci. USA (2003) 100:1844–1848.
  • •One of several reports describing the use of lentiviral RNAi vectors to generate knockdown mice.
  • MATTA H, HOZAYEV B, TOMAR R, CHUGH P, CHAUDHARY PM: Use of lentiviral vectors for delivery of small interfering RNA. Cancer Biol. Ther. (2003) 2:206–210.
  • SCHERR M, BATTMER K, GANSER A,EDER M: Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle (2003) 2:251–257.
  • AN DS, XIE Y, MAO SH et al.: Efficient lentiviral vectors for short hairpin RNA delivery into human cells. Hum. Gene Tiler: (2003) 14:1207–1212.
  • WIZNEROWICZ M, TRONO D: Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J. Virol. (2003) 77:8957–8961.
  • •Demonstrates that lentiviral RNAi vectors can be adapted for inducible siRNA expression.
  • SHEN C, BUCK AK, LIU X, WINKLER M, RESKE SN: Gene silencing by adenovirus-delivered siRNA. FEBS Lett. (2003) 539:111–114.
  • ARTS GJ, LANGEMEIJER E, TISSINGH R et al.: Adenoviral vectors expressing siRNAs for discovery and validation of gene function. Genome Res. (2003) 13:2325–2332.
  • ZHAO LJ, JIAN H, ZHU H: Specific gene inhibition by adenovirus-mediated expression of small interfering RNA. Gene (2003) 316:137–141.
  • TOMAR RS, MATTA H, CHAUDHARY PM: Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene (2003) 22:5712–5715.
  • LEWIS PF, EMERMAN M: Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. (1994) 68:510–516.
  • HATZIIOANNOU T, GOFF SP: Infectionof nondividing cells by Rous sarcoma virus. Virol. (2001) 75:9526–9531.
  • LEWIS P, HENSEL M, EMERMAN M: Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO (1992) 11:3053–3058.
  • QIN XF, AN DS, CHEN IS, BALTIMORE D: Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. USA (2003) 100:183–188.
  • •One of a series of reports demonstrating that lentiviral RNAi vectors can inhibit HIV replication in primary human T cells.
  • LI MJ, BAUER G, MICHIENZI A et al.: Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol. Ther. (2003) 8:196–206.
  • •One of a series of reports demonstrating that lentiviral RNAi vectors can inhibit HIV replication in primary human T cells.
  • MALIM MH, HAUBER J, LE SY, MAIZEL JV, CULLEN BR: The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature (1989) 338:254–257.
  • FELBER BK, HADZOPOULOU-CLADARAS M, CLADARAS C, COPELAND T, PAVLAKIS GN: rev protein of human immunodeficiency virus Type 1 affects the stability and transport of the viral mRNA. Proc. Natl. Acad. Sci. USA (1989) 86:1495–1499.
  • PARK F, KAY MA: Modified HIV-1 basedlentiviral vectors have an effect on viral transduction efficiency and gene expression in vitro and in vivo. Mol. The]: (2001) 4:164–173.
  • ZUFFEREY R, DONELLO JE, TRONO D, HOPE TJ: Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. Vim/. (1999) 73:2886–2892.
  • CHI JT, CHANG HY, WANG NN et al.: Genomewide view of gene silencing by small interfering RNAs. Proc. Nati Acad. Sci. USA (2003) 100:6343–6346.
  • SEMIZAROV D, FROST L, SARTHY A et al.: Specificity of short interfering RNA determined through gene expression signatures. Proc. Nati Acad. Sri. USA (2003) 100:6347–6352.
  • JACKSON AL, BARTZ SR, SCHELTER J et al.: Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. (2003) 21:635–637.
  • ••Suggests that siRNA may induce off-targetgene silencing.
  • BRIDGE AJ, PEBERNARD S, DUCRAUX A, NICOULAZ AL, IGGO R: Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. (2003) 34:263–264.
  • ••Demonstrates that RNAi vectors mayinduce an interferon response.
  • SLEDZ CA, HOLKO M, DE VEER MJ, SILVERMAN RH, WILLIAMS BR: Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. (2003) 5:834–839.
  • ••Demonstrates that siRNA may induce aninterferon response.
  • MACKENZIE TC, KOBINGER GP, KOOTSTRA NA et al: Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. MM. Ther. (2002) 6:349–358.
  • •One of several noteworthy papers demonstrating that pseudotyping can dramatically alter lentiviral tropism in vivo.
  • KANG Y, STEIN CS, HETH JA et al.: In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins.J. Virol (2002) 76:9378–9388.
  • •One of several noteworthy papers demonstrating that pseudotyping can dramatically alter lentiviral tropism in vivo.
  • MARTIN F, NEIL S, KUPSCH J et al.: Retrovirus targeting by tropism restriction to melanoma cells." Virol (1999) 73:6923–6929.
  • NGUYEN TH, LOUX N, DAGHER I et al.: Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met. Cancer Gene Ther. (2003) 10:840–849.
  • MORIZONO K, BRISTOL G, XIE YM, KUNG SK, CHEN IS: Antibody-directed targeting of retroviral vectors via cell surface antigens.Virol (2001) 75:8016–8020.
  • GOLLAN TJ, GREEN MR: Selective targeting and inducible destruction of human cancer cells by retroviruses with envelope proteins bearing short peptide ligands." Virol (2002) 76:3564–3569.
  • GOLLAN TJ, GREEN MR: Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope. Virol (2002) 76:3558–3563.
  • BUPP K, ROTH MJ: Targeting a retroviral vector in the absence of a known cell- targeting ligand. Hum. Gene Ther. (2003) 14:1557–1564.
  • •Presents a selection scheme for altering tropism by screening a library of envelopes containing random peptide insertions.
  • JACQUE JM, TRIQUES K, STEVENSON M: Modulation of HIV-1 replication by RNA interference. Nature (2002) 418:435–438.
  • LEE NS, DOHJIMA T, BAUER Get al.:Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol (2002) 20:500–505.
  • SURABHI RM, GAYNOR RB: RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication.
  • •Virol (2002) 76:12963–12973.
  • COBURN GA, CULLEN BR: Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference." Virol (2002) 76:9225–9231.
  • NOVINA CD, MURRAY MF, DYKXHOORN DM et al: siRNA-directed inhibition of HIV-1 infection. Nat. Med. (2002) 8:681–686.
  • SONG E, LEE SK, DYKXHOORN DM et al.: Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages.
  • •Virol (2003) 77:7174–7181.
  • MARTINEZ MA, GUTIERREZ A, ARMAND-UGON M et al.: Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS (2002) 16:2385–2390.
  • POLURI A, MAANEN MV, SUTTON RE: Genetic therapy for HIV/ AIDS. Expert Opin. Biol. The]: (2003) 3:951–963.
  • POESCHLA E, CORBEAU P, WONG-STAAL F: Development of HIV vectors for anti-HIV gene therapy. Proc. Natl. Acad. Sci. USA (1996) 93:11395–11399.
  • UCHIDA N, SUTTON RE, FRIERA AM et al.: HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated GO/G1 human hematopoietic stem cells. Proc. Nati Acad. Sci. USA (1998) 95:11939–11944.
  • MIYOSHI H, SMITH KA, MOSIER DE, VERMA IM, TORBETT BE: Transduction of human CD34+ cells that mediate long- term engraftment of NOD/SCID mice by HIV vectors. Science (1999) 283:682–686.
  • GATLIN J, PADGETT A, MELKUS MW,KELLY PF, GARCIA JV: Long-term engraftment of nonobese diabetic/severe combined immunodeficient mice with human CD34+ cells transduced by a self-inactivating human immunodeficiency virus type 1 vector. Hum. Gene The]: (2001) 12:1079–1089.
  • LEE MT, COBURN GA, MCCLURE MO, CULLEN BR: Inhibition of human immunodeficiency virus Type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. Virol (2003) 77: 11964-11972.
  • •Demonstrates that lentiviral RNAi vectors effectively inhibit HIV-1 replication in primary human macrophages.
  • BANERJEA A, LI MJ, BAUER G et al: Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. MM. Ther. (2003) 8:62–71.
  • ••Proof of concept for combating AIDS viareconstituting an HIV-resistant immune system using lentiviral RNAi vector-transduced CD34+ HSCs.
  • HILLEMAN MR: Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine (2003) 21:4626–4649.
  • WILSON JA, JAYASENA S, KHVOROVA A et al.: RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc. Nati Acad. Sci. USA (2003) 100:2783–2788.
  • RACANELLI V, REHERMANN B: Hepatitis C virus infection: when silence is deception. Trends Immunol. (2003) 24:456–464.
  • FLAMM SL: Chronic hepatitis C virus infection. JAMA (2003) 289:2413–2417.
  • YOKOTA T, SAKAMOTO N, ENOMOTO N et al.: Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. (2003) 4:602–608.
  • SEO MY, ABRIGNANI S, HOUGHTON M, HAN JH: Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J. Vim/. (2003) 77:810–812.
  • RANDALL G, GRAKOUI A, RICE CM: Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl. Acad. Sci. USA (2003) 100:235–240.
  • KAPADIA SB, BRIDEAU-ANDERSEN A,CHISARI FV: Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc. Natl. Acad. Sci. USA (2003) 100:2014–2018.
  • SHLOMAI A, SHAUL Y: Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology (2003) 37:764–770.
  • HAMASAKI K, NAKAO K, MATSUMOTO K et al.: Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett. (2003) 543:51–54.
  • MCCAFFREY AP, NAKAI H, PANDEY K et al: Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol (2003) 21:639–644.
  • ••One of two reports demonstrating thatsiRNA blocks HBV replication in mice.
  • YING C, DE CLERCQ E, NEYTS J: Selective inhibition of hepatitis B virus replication by RNA interference. Biochem. Biophys. Res. Commun. (2003) 309:482–484.
  • GILADI H, KETZINEL-GILAD M, RIVKIN L et al.: Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther. (2003) 8:769–776.
  • ••One of two reports demonstrating thatsiRNA blocks HBV replication in mice.
  • PFEIFER A, KESSLER T, YANG M et al.: Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. Mol The]: (2001) 3:319–322.
  • PARK F: Correction of bleeding diathesis without liver toxicity using arenaviral-pseudotyped HIV-1-based vectors in hemophilia A mice. Hum. Gene Ther. (2003) 14:1489–1494.
  • DAMM-WELK C, FUCHS U, WOSSMANN W, BORKHARDT A: Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference. Semin. Cancer Biol. (2003) 13:283–292.
  • KOVAR H, BAN J, POSPISILOVA S: Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin. Cancer Biol. (2003) 13:275–281.
  • DUURSMA AM, AGAMI R: Ras interference as cancer therapy. Semin. Cancer Biol. (2003) 13:267–273.
  • YOSHINOUCHI M, YAMADA T, KIZAKI M et al.: ha vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by e6 siRNA. Mol. Ther. (2003) 8:762–768.
  • ••Demonstrates that siRNA-mediatedoncogene silencing reduces turnourigenicity in vivo.
  • SCHERR M, BATTMER K, WINKLER T et al.: Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood (2003) 101:1566–1569.
  • WOHLBOLD L, VAN DER KUIP H, MIETHING C et al.: Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (5TI571). Blood(2003) 102:2236–2239.
  • ••Highlights potential usefulness of combinedRNAi/chemotherapeutic interventions.
  • WOOD MJ, TRULZSCH B, ABDELGANY A, BEESON D: Ribozymes and siRNA for the treatment of diseases of the nervous system. Carr: Opin. Mol The]: (2003) 5:383–388.
  • WOOD MJ, TRULZSCH B, ABDELGANY A, BEESON D: Therapeutic gene silencing in the nervous system. Hum. Mol Genet. (2003) 12(Spec. No. 2):R279–R284.
  • ESCARPE P, ZAYEK N, CHIN P et al: Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV- based vector preparations. Ma Ther. (2003) 8:332–341.
  • KOHN DB, SADELAIN M, DUNBAR C et al.: American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Ma The]: (2003) 8:180–187.
  • ••Important commentary on retroviral genetherapy of HSCs.
  • HACEIN-BEY-ABINA S, LE DEIST F, CARLIER F et al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. (2002) 346:1185–1193.
  • AIUTI A, SLAVIN S, AKER M et al: Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 296:2410–2413.
  • HACEIN-BEY-ABINA S, VON KALLE C, SCHMIDT M et al.: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl. J. Med. (2003) 348:255–256.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.